|
1
|
El-Serag HB: Hepatocellular carcinoma. N
Engl J Med. 365:1118–1127. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Breuhahn K: Molecular mechanisms of
progression in human hepatocarcinogenesis. Pathologe (31.
(Suppl):2:S170–S176. 2010.(In German). View Article : Google Scholar
|
|
5
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard
P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A,
et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J
Med. 359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dhanasekaran R, Limaye A and Cabrera R:
Hepatocellular carcinoma: Current trends in worldwide epidemiology,
risk factors, diagnosis, and therapeutics. Hepat Med. 4:19–37.
2012.PubMed/NCBI
|
|
7
|
Nguyen VT, Law MG and Dore GJ: Hepatitis
B-related hepatocellular carcinoma: Epidemiological characteristics
and disease burden. J Viral Hepat. 16:453–463. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Schwartz M: Liver transplantation for
hepatocellular carcinoma. Gastroenterology. 127:S268–S276. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lencioni R: Chemoembolization in patients
with hepatocellular carcinoma. Liver Cancer. 1:41–50. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Decaens T, Roudot-Thoraval F,
Bresson-Hadni S, Meyer C, Gugenheim J, Durand F, Bernard PH,
Boillot O, Boudjema K, Calmus Y, et al: Impact of
pretransplantation transarterial chemoembolization on survival and
recurrence after liver transplantation for hepatocellular
carcinoma. Liver Transpl. 11:767–775. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yao FY, Kinkhabwala M, LaBerge JM, Bass
NM, Brown R Jr, Kerlan R, Venook A, Ascher NL, Emond JC and Roberts
JP: The impact of pre-operative loco-regional therapy on outcome
after liver transplantation for hepatocellular carcinoma. Am J
Transplant. 5:795–804. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang YX, De Baere T, Idee JM and Ballet S:
Transcatheter embolization therapy in liver cancer: An update of
clinical evidences. Chin J Cancer Res. 27:96–121. 2015.PubMed/NCBI
|
|
13
|
Bouchard-Fortier A, Lapointe R, Perreault
P, Bouchard L and Pomier-Layrargues G: Transcatheter arterial
chemoembolization of hepatocellular carcinoma as a bridge to liver
transplantation: A retrospective study. Int J Hepatol.
2011:9745142011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gordon-Weeks AN, Snaith A, Petrinic T,
Friend PJ, Burls A and Silva MA: Systematic review of outcome of
downstaging hepatocellular cancer before liver transplantation in
patients outside the Milan criteria. Br J Surg. 98:1201–1208. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Millonig G, Graziadei IW, Freund MC,
Jaschke W, Stadlmann S, Ladurner R, Margreiter R and Vogel W:
Response to preoperative chemoembolization correlates with outcome
after liver transplantation in patients with hepatocellular
carcinoma. Liver Transpl. 13:272–279. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang Z, Liu Q, He J, Yang J, Yang G and
Wu M: The effect of preoperative transcatheter hepatic arterial
chemoembolization on disease-free survival after hepatectomy for
hepatocellular carcinoma. Cancer. 89:2606–2612. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Otto G, Herber S, Heise M, Lohse AW, Mönch
C, Bittinger F, Hoppe-Lotichius M, Schuchmann M, Victor A and
Pitton M: Response to transarterial chemoembolization as a
biological selection criterion for liver transplantation in
hepatocellular carcinoma. Liver Transpl. 12:1260–1267. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kasprzak A, Kwasniewski W, Adamek A and
Gozdzicka- Jozefiak A: Insulin-like growth factor (IGF) axis in
cancerogenesis. Mutat Res Rev Mutat Res. 772:78–104. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wu J and Zhu AX: Targeting insulin-like
growth factor axis in hepatocellular carcinoma. J Hematol Oncol.
4:302011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Elmashad N, Ibrahim WS, Mayah WW, Farouk
M, Ali LA, Taha A and Elmashad W: Predictive value of serum
insulin-like growth factor-1 in hepatocellular carcinoma. Asian Pac
J Cancer Prev. 16:613–619. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Espelund U, Gronbaek H, Villadsen GE,
Simonsen K, Vestergaard PF, Jørgensen JO, Flyvbjerg A, Vilstrup H
and Frystyk J: The circulating IGF system in hepatocellular
carcinoma: The impact of liver status and treatment. Growth Horm
IGF Res. 25:174–181. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mazziotti G, Sorvillo F, Morisco F,
Carbone A, Rotondi M, Stornaiuolo G, Precone DF, Cioffi M, Gaeta
GB, Caporaso N and Carella C: Serum insulin-like growth factor I
evaluation as a useful tool for predicting the risk of developing
hepatocellular carcinoma in patients with hepatitis C virus-related
cirrhosis: A prospective study. Cancer. 95:2539–2545. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rehem RN and El-Shikh WM: Serum IGF-1,
IGF-2 and IGFBP-3 as parameters in the assessment of liver
dysfunction in patients with hepatic cirrhosis and in the diagnosis
of hepatocellular carcinoma. Hepatogastroenterology. 58:949–954.
2011.PubMed/NCBI
|
|
24
|
Su WW, Lee KT, Yeh YT, Soon MS, Wang CL,
Yu ML and Wang SN: Association of circulating insulin-like growth
factor 1 with hepatocellular carcinoma: One cross-sectional
correlation study. J Clin Lab Anal. 24:195–200. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chun YS, Huang M, Rink L and Von Mehren M:
Expression levels of insulin-like growth factors and receptors in
hepatocellular carcinoma: A retrospective study. World J Surg
Oncol. 12:2312014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dong Z, Yao M, Wang L, Yan X, Gu X, Shi Y,
Yao N, Qiu L, Wu W and Yao D: Abnormal expression of insulin-like
growth factor-I receptor in hepatoma tissue and its inhibition to
promote apoptosis of tumor cells. Tumour Biol. 34:3397–3405. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Souza RF, Wang S, Thakar M, Smolinski KN,
Yin J, Zou TT, Kong D, Abraham JM, Toretsky JA and Meltzer SJ:
Expression of the wild-type insulin-like growth factor II receptor
gene suppresses growth and causes death in colorectal carcinoma
cells. Oncogene. 18:4063–4068. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chen Z, Ge Y, Landman N and Kang JX:
Decreased expression of the mannose 6-phosphate/insulin-like growth
factor-II receptor promotes growth of human breast cancer cells.
BMC Cancer. 2:182002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lu ZL, Luo DZ and Wen JM: Expression and
significance of tumor-related genes in HCC. World J Gastroenterol.
11:3850–3854. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Causin C, Waheed A, Braulke T, Junghans U,
Maly P, Humbel RE and von Figura K: Mannose
6-phosphate/insulin-like growth factor II-binding proteins in human
serum and urine. Their relation to the mannose
6-phosphate/insulin-like growth factor II receptor. Biochem J.
252:795–799. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Jirtle RL, Hankins GR, Reisenbichler H and
Boyer IJ: Regulation of mannose 6-phosphate/insulin-like growth
factor-II receptors and transforming growth factor beta during
liver tumor promotion with phenobarbital. Carcinogenesis.
15:1473–1478. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kornfeld S: Structure and function of the
mannose 6-phosphate/insulinlike growth factor II receptors. Annu
Rev Biochem. 61:307–330. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Denley A, Cosgrove LJ, Booker GW, Wallace
JC and Forbes BE: Molecular interactions of the IGF system.
Cytokine Growth Factor Rev. 16:421–439. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Enguita-German M and Fortes P: Targeting
the insulin-like growth factor pathway in hepatocellular carcinoma.
World J Hepatol. 6:716–737. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chu CH, Huang CY, Lu MC, Lin JA, Tsai FJ,
Tsai CH, Chu CY, Kuo WH, Chen LM and Chen LY: Enhancement of
AG1024-induced H9c2 cardiomyoblast cell apoptosis via the
interaction of IGF2R with Galpha proteins and its downstream PKA
and PLC-beta modulators by IGF-II. Chin J Physiol. 52:31–37. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chu CH, Tzang BS, Chen LM, Kuo CH, Cheng
YC, Chen LY, Tsai FJ, Tsai CH, Kuo WW and Huang CY:
IGF-II/mannose-6-phosphate receptor signaling induced cell
hypertrophy and atrial natriuretic peptide/BNP expression via
Galphaq interaction and protein kinase C-alpha/CaMKII activation in
H9c2 cardiomyoblast cells. J Endocrinol. 197:381–390. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang KC, Brooks DA, Botting KJ and
Morrison JL: IGF-2R-mediated signaling results in hypertrophy of
cultured cardiomyocytes from fetal sheep. Biol Reprod. 86:1832012.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Dennis PA and Rifkin DB: Cellular
activation of latent transforming growth factor beta requires
binding to the cation-independent mannose 6-phosphate/insulin-like
growth factor type II receptor. Proc Natl Acad Sci USA. 88:580–584.
1991. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ghosh P, Dahms NM and Kornfeld S: Mannose
6-phosphate receptors: New twists in the tale. Nat Rev Mol Cell
Biol. 4:202–212. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Nahon P and Zucman-Rossi J: Single
nucleotide polymorphisms and risk of hepatocellular carcinoma in
cirrhosis. J Hepatol. 57:663–674. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Weng CJ, Hsieh YH, Tsai CM, Chu YH, Ueng
KC, Liu YF, Yeh YH, Su SC, Chen YC, Chen MK, et al: Relationship of
insulin-like growth factors system gene polymorphisms with the
susceptibility and pathological development of hepatocellular
carcinoma. Ann Surg Oncol. 17:1808–1815. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Rezgui D, Williams C, Savage SA, Prince
SN, Zaccheo OJ, Jones EY, Crump MP and Hassan AB: Structure and
function of the human Gly1619Arg polymorphism of M6P/IGF2R domain
11 implicated in IGF2 dependent growth. J Mol Endocrinol.
42:341–356. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
DaCosta SA, Schumaker LM and Ellis MJ:
Mannose 6-phosphate/insulin-like growth factor 2 receptor, a bona
fide tumor suppressor gene or just a promising candidate? J Mammary
Gland Biol Neoplasia. 5:85–94. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
EASL Clinical Practice Guidelines:
Management of hepatocellular carcinoma. J Hepatol. 69:182–236.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Geller DS, Morris J, Revskaya E, Kahn M,
Zhang W, Piperdi S, Park A, Koirala P, Guzik H, Hall C, et al:
Targeted therapy of osteosarcoma with radiolabeled monoclonal
antibody to an insulin-like growth factor-2 receptor (IGF2R). Nucl
Med Biol. 43:812–817. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Lee JS, Weiss J, Martin JL and Scott CD:
Increased expression of the mannose 6-phosphate/insulin-like growth
factor-II receptor in breast cancer cells alters tumorigenic
properties in vitro and in vivo. Int J Cancer. 107:564–570. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
O'Gorman DB, Weiss J, Hettiaratchi A,
Firth SM and Scott CD: Insulin-like growth factor-II/mannose
6-phosphate receptor overexpression reduces growth of
choriocarcinoma cells in vitro and in vivo. Endocrinology.
143:4287–4294. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Otto G, Heise M, Moench C, Herber S,
Bittinger F, Schuchmann M, Hoppe-Lotichius M and Pitton M:
Transarterial chemoembolization before liver transplantation in 60
patients with hepatocellular carcinoma. Transplant Proc.
39:537–539. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Shneor D, Folberg R, Pe'er J, Honigman A
and Frenkel S: Stable knockdown of CREB, HIF-1 and HIF-2 by
replication-competent retroviruses abrogates the responses to
hypoxia in hepatocellular carcinoma. Cancer Gene Ther. 24:64–74.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Harris AL: Hypoxia-A key regulatory factor
in tumour growth. Nat Rev Cancer. 2:38–47. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Rashad NM, El-Shal AS, Abd Elbary EH, Abo
Warda MH and Hegazy O: Impact of insulin-like growth factor 2,
insulin-like growth factor receptor 2, insulin receptor substrate 2
genes polymorphisms on susceptibility and clinicopathological
features of hepatocellular carcinoma. Cytokine. 68:50–58. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
de Bleser PJ, Jannes P, van Buul-Offers
SC, Hoogerbrugge CM, van Schravendijk CF, Niki T, Rogiers V, van
den Brande JL, Wisse E and Geerts A: Insulinlike growth
factor-II/mannose 6-phosphate receptor is expressed on
CCl4-exposed rat fat-storing cells and facilitates
activation of latent transforming growth factor-beta in cocultures
with sinusoidal endothelial cells. Hepatology. 21:1429–1437. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Brandao DF, Ramalho LN, Ramalho FS,
Zucoloto S, Martinelli Ade L and Silva Ode C: Liver cirrhosis and
hepatic stellate cells. Acta Cir Bras. 1:54–57. 2006. View Article : Google Scholar
|
